Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05970497 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | PHASE1 | RECRUITING | 240 | — | — | Oct 31, 2023 | Jul 1, 2027 | May 18, 2025 | 15 | United States |
Percentage of subjects with adverse events (AEs)
Percentage of subjects with serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| Cohorts 1 through 4 | EXPERIMENTAL | Dose escalation and expansion cohorts: KB707 monotherapy in subjects with solid tumors. |
| Cohort 5 | EXPERIMENTAL | Dose expansion cohort: KB707 administered in combination with Opdualag in approximately 100 subjects with advanced melanoma. |
| Cohort 6 | EXPERIMENTAL | Dose expansion cohort: KB707 administered in combination with Keytruda in approximately 100 subjects with advanced melanoma. |
| Name | Type | Description |
|---|---|---|
| KB707 | BIOLOGICAL | Genetically modified herpes simplex type 1 virus |
| Opdualag | DRUG | Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors) |
| KEYTRUDA ®( Pembrolizumab) | DRUG | Immunotherapy (PD-1 immune checkpoint inhibitor) |
Key Inclusion Criteria: * Life expectancy \>12 weeks * ECOG performance status of 0 or 1 * Have measurable disease per RECIST v1.1 at Screening * Cohorts 1-4 only: Histologically confirmed diagnosis of a locally advanced or metastatic solid tumor and the individual has progressed on standard of car...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |